Clinical trials: Pachyonychia Congenita
Pachyonychia Congenita
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.
- Trial name
- NCT03920228
- Testing
- PTX-022
- Where
- 9 sites in United States
- Volunteers
- 73 people
- Sponsor
- Palvella Therapeutics, Inc.
Pachyonychia Congenita
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study.
- Trial name
- VALO-2 (NCT04520750)
- Testing
- PTX-022
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Palvella Therapeutics, Inc.
Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
- Trial name
- VAPAUS (NCT05180708)
- Testing
- QTORIN 3.9% rapamycin anhydrous gel, Vehicle
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 87 people
- Sponsor
- Palvella Therapeutics, Inc.
Pachyonychia Congenita
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS)…
- Trial name
- NCT05643872
- Testing
- PTX-022
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Palvella Therapeutics, Inc.
Pachyonychia Congenita
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time.
- Trial name
- NCT02152007
- Testing
- 1% sirolimus cream (TD201 1%)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- TransDerm, Inc.